| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Stanford Stroke Center, Department of Neurology and Neurological Sciences, Stanford University Medical Center, Palo Alto, CA.
Address correspondence and reprint requests to Dr. Gregory W. Albers, Stanford Stroke Center, 701 Welch Road, Suite 325, Palo Alto, CA 94304; e-mail: albers{at}leland.stanford.edu
The relative efficacies of different antiplatelet agents for stroke prevention are unclear because of differences in clinical trial design, a lack of direct comparisons between individual agents, and differences in the choice of primary endpoints. Individual endpoints in a clinical trial are often combined into a single primary endpoint cluster. Theoretically, a combined endpoint may reduce the sample size required to demonstrate significant benefits of an effective therapy. However, unless all components of a composite endpoint are affected in the same direction and to a similar degree, their inclusion may not provide the anticipated increase in statistical power. In fact, the use of a combined endpoint may lead to an underestimate of therapeutic benefits when patients at high risk for one particular endpoint are studied. For patients with stroke or TIA, the single outcome of stroke is particularly important because these patients have a higher risk of recurrent stroke than any other vascular outcome during the initial years after a stroke. Because of the low incidence of myocardial infarction (MI) in stroke trials, the inclusion of MI in the primary endpoint will usually have minimal influence on trial outcome, and antiplatelet therapy has not been shown to be beneficial in preventing nonvascular death. Chance variations in the incidence of MI or death may detract from the benefit of the agent for stroke prevention when it is included in a combined endpoint. The benefit of antiplatelet therapies for patients with recent cerebrovascular events is determined most accurately if stroke alone is chosen as the primary endpoint.
Key words: Antiplatelet therapy—Clinical trials—Outcome—Risk—Stroke prevention.
This article has been cited by other articles:
|
|
 |
|
  G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 630S - 669S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Thijs, R. Lemmens, and S. Fieuws Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke Eur. Heart J., May 1, 2008; 29(9): 1086 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Bravata, S.-Y. Ho, T. P. Meehan, L. M. Brass, and J. Concato Readmission and Death After Hospitalization for Acute Ischemic Stroke: 5-Year Follow-Up in the Medicare Population Stroke, June 1, 2007; 38(6): 1899 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Gongora-Rivera, J. Labreuche, A. Jaramillo, P. G. Steg, J.-J. Hauw, and P. Amarenco Autopsy Prevalence of Coronary Atherosclerosis in Patients With Fatal Stroke Stroke, April 1, 2007; 38(4): 1203 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Skali, M. A. Pfeffer, J. Lubsen, and S. D. Solomon Variable Impact of Combining Fatal and Nonfatal End Points in Heart Failure Trials Circulation, November 21, 2006; 114(21): 2298 - 2303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Dhamoon, R. R. Sciacca, T. Rundek, R. L. Sacco, and M.S.V. Elkind Recurrent stroke and cardiac risks after first ischemic stroke: The Northern Manhattan Study Neurology, March 14, 2006; 66(5): 641 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bates, J. Y. Choi, P. W. Duncan, J. J. Glasberg, G. D. Graham, R. C. Katz, K. Lamberty, D. Reker, and R. Zorowitz Veterans Affairs/Department of Defense Clinical Practice Guideline for the Management of Adult Stroke Rehabilitation Care: Executive Summary Stroke, September 1, 2005; 36(9): 2049 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S.V. Elkind Implications of stroke prevention trials: Treatment of global risk Neurology, July 12, 2005; 65(1): 17 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Jamieson, A. Parekh, and M. D. Ezekowitz Review of Antiplatelet Therapy in Secondary Prevention of Cerebrovascular Events: A Need for Direct Comparisons Between Antiplatelet Agents Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2005; 10(3): 153 - 161. [Abstract] [PDF]
|
|
|
|
 |
|
 R. L. Sacco, J. Sivenius, and H.-C. Diener Efficacy of Aspirin Plus Extended-Release Dipyridamole in Preventing Recurrent Stroke in High-Risk Populations Arch Neurol, March 1, 2005; 62(3): 403 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 483S - 512S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Coull Statin Therapy After Acute Ischemic Stroke in the Heart Protection Study: Is the Role in Recurrent Stroke Prevention Now Defined? Stroke, September 1, 2004; 35(9): 2233 - 2234. [Full Text] [PDF]
|
|
|
|
|
|
M. Moonis and M. Fisher Considering the Role of Heparin and Low-Molecular-Weight Heparins in Acute Ischemic Stroke Stroke, July 1, 2002; 33(7): 1927 - 1933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Muir Heterogeneity of Stroke Pathophysiology and Neuroprotective Clinical Trial Design Stroke, June 1, 2002; 33(6): 1545 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. van Gijn The PROGRESS Trial: Preventing Strokes by Lowering Blood Pressure in Patients With Cerebral Ischemia: Emerging Therapies: Critique of an Important Advance Stroke, January 1, 2002; 33(1): 319 - 320. [Full Text] [PDF]
|
|
|
|
|
|
G. W. Albers and P. Amarenco Combination Therapy With Clopidogrel and Aspirin: Can the CURE Results Be Extrapolated to Cerebrovascular Patients? Stroke, December 1, 2001; 32(12): 2948 - 2949. [Full Text] [PDF]
|
|
|
|
|
|
M. S.V. Elkind Implications of stroke prevention trials: Treatment of global risk Neurology, July 12, 2005; 65(1): 17 - 21. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
